NORRIS MEDICINES LIMITED

Towards Change

Factory : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 6th November, 2026

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

Script Code: 524414

Sub.: Intimation under regulation 29 of SEBI (Listing Obligations and Disclosure Requirements), 2015 for consideration and approval of Un-audited financial results for the quarter and half year ended September 30th, 2026 and other matters.

Dear Sir,

This is to inform you that, the meeting of the Board of Directors of the Company Norris Medicines Limited scheduled to be held on **Saturday, 14th November, 2026** at the Registered office of the Company situated at Plot No.801/P, GIDC, Ankleshwar, Gujarat, 393002, to transact the following business:

1. To consider and approve Un-audited Financial Results for the quarter and half year ended 30th September, 2026 along with Limited Review Report thereof.
2. Any other business with permission of Chair.

Further, as communicated earlier, in accordance with Company's Code of Conduct for Prevention of Insider Trading in securities of the Company and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in securities of the Company is already closed from October 01, 2026 until Forty-Eight (48) hours after declaration of Un-audited financial results for the quarter and half year ended September 30, 2026 on Stock Exchange.

Kindly take the same on your records.

Thanking You,
Yours truly,
FOR NORRIS MEDICINES LIMITED

VIMAL D SHAH
Digitally signed by VIMAL D SHAH
Date: 2026.11.06 11:15:51 +05'30'

VIMAL SHAH
MANAGING DIRECTOR
DIN: 01506655